How to Prevent Muscle Loss on Wegovy, Zepbound, or Ozempic: A Guide for Women

The number on the scale is the least interesting thing about GLP-1 weight loss. I say that to every woman who starts one, and most of them think I'm being contrarian until we run a body composition scan three months in. The scale says she's lost twenty-two pounds. The scan says seven of them were muscle. She feels it, too — the stairs are harder, the grocery bags are heavier, and she's tired in a way the weight loss was supposed to fix.

This is the part of the GLP-1 story that has finally reached the research community, which is why two muscle-preserving drugs designed to be taken alongside GLP-1s produced headline results this year. But you don't need to wait for those. The protocol that protects muscle and bone during rapid weight loss exists now, it's not complicated, and in a woman over forty it is not optional.

Why this is a midlife problem specifically

When anyone loses weight quickly, some of it comes from lean tissue. Trials of GLP-1 medications have generally found that roughly 25 to 40 percent of the weight lost is lean mass rather than fat. The body is in a large caloric deficit, protein intake usually drops because appetite is gone, and without a reason to keep muscle — a load on it — the body treats it as expendable.

A woman in perimenopause or beyond is already losing muscle and bone on her own. Estrogen supports both; as it declines, the rate of loss accelerates, and after fifty most women are losing muscle every year without a medication speeding it along. Add rapid GLP-1 weight loss on top of that trajectory and you can produce a body that is lighter, weaker, and more fragile — with lower bone density, a lower resting metabolic rate, and less of the tissue that clears glucose from the blood. That last point is the irony: muscle is the main site of insulin sensitivity, and losing it undermines the metabolic improvement the drug was meant to deliver.

What the new drugs showed

Two trials this year put numbers on what's possible when muscle is deliberately protected. The BELIEVE study, published in Nature Medicine in March, combined semaglutide with bimagrumab, an antibody that blocks the signaling that limits muscle growth. In the high-dose combination group, roughly 92 percent of the weight lost was fat — compared with about 72 percent on semaglutide alone — and total weight loss was greater with the combination than with either drug by itself. Bimagrumab on its own actually increased lean mass while reducing fat.

The EMBRAZE trial, published in June, paired tirzepatide with apitegromab, a selective myostatin inhibitor, and found the combination preserved about 55 percent of the lean mass that would otherwise have been lost, with total weight loss essentially unchanged. Notably, more than 80 percent of the participants were women.

Neither drug is approved, both are given by infusion or injection, and both are years from a pharmacy. What they prove is the principle: when you stop the muscle from being lost, the weight loss is better in every way that matters. And there is a version of that intervention you can do yourself, starting on day one.

The protocol I build around every GLP-1 prescription

Protein: roughly 1.2 to 1.6 grams per kilogram of body weight daily, spread across meals. For a 165-pound woman that's about 90 to 120 grams — and it's the hardest part, because the medication removes the appetite that would normally get you there. Eat protein first at every meal, before anything else fills you up, and treat a protein shake as medicine on days when food doesn't appeal. Under-eating protein on a GLP-1 is the single most common way women lose muscle on it.
Resistance training two to three times a week, progressively heavier. Muscle stays when it's asked to work. Walking is excellent for glucose and mood, but it is not a signal to keep muscle; lifting is. If you've never lifted, this is the moment to learn with someone who can teach form — the goal is compound movements, real load, and adding weight over time.
Measure body composition, not weight. A DEXA scan before starting and every three to four months tells you what you're actually losing. If lean mass is dropping faster than a modest share of the total, the protein and training need adjusting before you go up another dose. A bioimpedance scale is a rougher tool but better than a bathroom scale.
Get a bone density baseline. If you're over forty-five, or have any risk factor for osteopenia, a DEXA bone scan before starting is the reference point you'll want in two years.
Slow the escalation if you're losing too fast. The dose schedules were written to reach a target dose, not to protect your skeleton. Losing more than about one percent of body weight a week for weeks on end is where lean-mass loss accelerates. A slower titration, held at a dose that produces steady rather than dramatic loss, is often the better plan in midlife.
Creatine, vitamin D, and omega-3s. Creatine monohydrate has real evidence for preserving muscle and strength in post-menopausal women and is inexpensive; vitamin D with K2 supports the bone side; the professional-grade versions are in my Fullscript dispensary. These are supports for the protein and the training, not substitutes.
Check the hormones. A woman whose estrogen and testosterone are at the floor will struggle to hold muscle no matter how well she eats and trains. If you're post-menopausal and on a GLP-1, the hormone therapy conversation belongs in the same appointment.

What to watch for

Strength going down while the scale goes down is the warning sign. So is a resting heart rate that climbs, fatigue that worsens as weight drops, hair shedding beyond the first few weeks, and a face or arms that look older rather than leaner. None of those are the drug working. They're the protocol failing, and they respond to more protein, more load, and a slower dose.

The GLP-1 medications are remarkable tools, and the muscle-preserving drugs coming behind them will make them better. But the thing those trials demonstrated — that protecting muscle turns weight loss into fat loss — is available to you now, for the price of a protein target, a barbell, and a scan. Build it in from the first dose. It is far easier to keep muscle than to rebuild it at fifty-five.

References

Drug Topics. “Results Show Bimagrumab With Semaglutide Achieve Substantial Weight Reduction” (BELIEVE phase 2, Nature Medicine), March 2026. View source
Pennington Biomedical Research Center. “Combination GLP-1 Therapy Shows Fat Mass Loss While Preserving Lean Mass in Adults with Obesity.” March 5, 2026. View source
Pratley RE, et al. “Apitegromab for lean mass preservation during tirzepatide-induced weight loss: a randomized, double-blind, placebo-controlled phase 2 trial.” Nature Medicine, 2026. View source
HealthDay. “Apitegromab Preserves Lean Mass When Combined With Tirzepatide.” June 15, 2026. View source

Bimagrumab and apitegromab are investigational and not FDA-approved. Regulatory status was checked against FDA materials current at the time of publication.